Im­muneer­ing cuts neu­ro­science pro­grams to fo­cus on on­col­o­gy, ex­tend cash run­way

Im­muneer­ing has sus­pend­ed its dis­cov­ery-stage neu­ro­science pro­gram and is now fo­cus­ing ex­clu­sive­ly on its on­col­o­gy pipeline in or­der to ex­tend its cash run­way in­to 2024, the com­pa­ny an­nounced in its Q4 re­lease.

The com­pa­ny’s lead pro­gram, IMM-1-104, is cur­rent­ly in a US-based Phase I/IIa study in pa­tients with ad­vanced sol­id tu­mors with RAS mu­ta­tions. In Sep­tem­ber last year, the can­di­date re­ceived IND clear­ance as an oral, once-dai­ly monother­a­py. Im­muneer­ing hopes to ex­tend it to oth­er can­cers, in­clud­ing mu­tat­ed pan­cre­at­ic, melanoma, lung and col­orec­tal can­cers, based on Phase I re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER